Endomimetics - Natural Bionanomatrix Coating Technologies
In many medical settings, devices are commonly used to help doctors treat patients. For example, stents are often used to open blocked arteries, repair torn vessels, and even to keep nasal passages from swelling shut after surgery. Unfortunately these devices fail often resulting in additional surgeries and often replacements of the original device.
Details:
Endomimetics has developed a BioNanomatrix that can be used to coat these devices and mimic human tissue which minimizes the need for additional surgeries, improves the longevity of the device, reduces complications associated with having foreign items implanted in your body.
Applications
Our endothelium mimicking nitric oxide releasing BioNanomatrix, initially developed for coronary and peripheral stents, is being assessed for several novel applications including:
- Stents to help with heart disease
- Stents and blood flow diverters to help with brain aneurysms
- Fistula implantation for dialysis patients
- Intranasal implants for chronic sinusitis sufferers
Technology Applications:
The Endomimetics bionanomatrix provides the following key attributes:
- A reservoir for sustained release of nitric oxide, which stimulates healthy normal endothelial cell coverage while limiting smooth muscle cell proliferation and platelet adhesion. The sustained release of nitric oxide promotes normal healthy vasodilation.
- An endothelial cell adhesive molecule, which promotes retention of endothelial cells.
- Self-assembling amino acid chains that are free of solvents typically used in device coatings, which may cause inflammation or be toxic
Advantages of the Endomimetics Bionanomatrix coating:
- Inhibits blood clot formation
- Inhibits renarrowing within a stent or implant
- Encourages healing of the normal arterial lining
- Lacks residual polymer or solvent
- Comprised of completely natural, peptide-based nanofibers
Brain Aneurysm
More than 3% of the population has unruptured cerebral aneurysms, approximately 10 million people in the US. About 30,000 rupture per year, with devastating consequences. More than 30% of patients with ruptured aneurysms die, and 4 of 7 who survive have significant disabilities. Detachable microcoils are now used in more than 70% of treated aneurysms. The risk of recurrence, or recanalization, remains surprisingly high at approximately 20-30%. Various modifications are used clinically with limited evidence that they provide improvement over bare coils. An important factor to improve clinical efficacy of the coils is to enhance endothelization, leading to durable occlusion.
Endomimetics has developed a nanomatrix coating that mimics the characteristic properties of native endothelium. Endomimetics scientists are demonstrating that the nanomatrix coating on the coil can enhance healing, thereby promoting durable closure of aneurysms. The coating provides sustained release of nitric oxide over 2 months, thus recruiting and retaining endothelial cells and endothelial progenitor cells. It also incorporates an endothelial cell adhesive ligand that promotes endothelial cell retention and migration. This coating method minimizes the risk of inflammatory responses. Coating of aneurysm coils is undergoing preclinical evaluation in collaboration with a group at the Mayo Clinic.a
Cardiovascular Disease
Stents are the most common cardiovascular implants used in the treatment of cardiovascular diseases. However, there are concerns about in-stent renarrowing (restenosis) with bare metal stents and late stent thrombosis and inflammatory responses with drug-eluting stents. The endothelium is the lining of the blood vessels that is a thin layer of endothelial cells and underlying nanofibrillar basement membrane. It modulates vascular tone by release of factors such as nitric oxide. With stent deployment, there is inevitable injury to the endothelium, triggering a cascade of restenosis and thrombosis.
The Endomimetics bionanomatrix coating provides a prohealing environment, enhancing healing of the endothelial lining, inhibiting blood clot formation, and limiting restenosis. The coating is undergoing preclinical evaluation for coronary stents at the University of Alabama at Birmingham.
Dialysis Fistula
More than 500,000 U.S. patients have end stage renal disease, and over 80% of them utilize hemodialysis. A significant problem for dialysis patients is the development of a functioning and durable vascular access, preferably an arteriovenous fistula (AVF). After creation, about 60% of AVFs fail to mature successfully for dialysis use. This is due to inadequate vasodilation and smooth muscle cell hyperplasia at the distal venous anastomosis.
A vascular wrap and gel incorporating the Endomimetics bionanomatrix has been developed. These are used to wrap the AVF at the time of creation, recruiting endothelial cells and enhancing appropriate vasodilation, both necessary for proper maturation. Additionally, the coating limits smooth muscle cell proliferation, which is also of benefit in that smooth muscle proliferation plays a significant role in AVF non-maturation. This wrap coating is undergoing preclinical evaluation in collaboration with a group at the University of Alabama at Birmingham,
Customer reviews
No reviews were found for Endomimetics - Natural Bionanomatrix Coating Technologies. Be the first to review!